FOR IMMEDIATE RELEASE March 26, 2002 CritiTech, Inc. reports that its nano-formulation of paclitaxel is more effective than the conventional paclitaxel in a mouse model of ovarian cancer. CritiTech today reported on the first animal data studying its proprietary and novel nano-particle preparation of paclitaxel. In a presentation today at the Kathy Roby, Ph.D., has submitted the results of a recent study on ovarian cancer to the American Society of Clinical Pharmacology Therapeutics Annual Meeting to be held in Atlanta, Georgia, March 24-27, 2002. Dr. Kathy Roby, is a Research Associate Professor of the Department of Anatomy and Cell Biology, and an Associate Director of the Cell and Tissue Culture Core at the Center for Reproductive Sciences, both at the University of Kansas Medical Center in Kansas City, Kansas, reported on enhanced survival in mice treated with CritiTech’s nanopaclitaxel versus those treated with conventional paclitaxel. CritiTech’s nanoparticulate paclitaxel significantly increased survival compared to control and paclitaxel treated mice. Control mice survived 87 days and paclitaxel treated mice survived 105 days. Significantly, up to 50% of the mice in the nanoparticulate paclitaxel groups were surviving at 162 days. Furthermore, the mice treated with the nanoparticulate paclitaxel exhibited no apparent toxicity to the highest dose. Treatment with nanoparticulate paclitaxel resulted in increased survival and reduced treatment related toxicity in a mouse model of ovarian cancer. Paclitaxel, a gift from NaPro, has shown promise in the treatment of ovarian cancer. However, toxicity, in part due to the insoluble nature of paclitaxel, remains a limitation to its use. The studies were undertaken to assess the effectiveness of a novel preparation of nanoparticulate paclitaxel in a mouse model of ovarian cancer. These preliminary data suggest that CritiTech’s proprietary nanopaclitaxel formulation may have both safety and efficacy advantages over conventional paclitaxel. For a copy of the full abstract that has been submitted, contact Kerri Johnson at kerri@lrtc.biz or (785) 749-3919. For further information please contact: |
 |
|
|
|
